...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Good points fuzzy.

I think this is still an academic/research institution and will be until management is changed.

However, it is very exciting news and good partnering.

If shareholders are ever to benefit we need a new management team.

GLTA

Toinv

6 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply